Assessment of the natural history of coronary artery calcification and identification of its determinants. Rationale of the 2nd part of the Heinz Nixdorf Recall Study;Analyse des natürlichen verlaufs der koronargefäßverkalkung und identifizierung ihrer determinanten. Rationale des 2. teils der Heinz Nixdorf Recall Studie

Herz

Volumn 32, Issue 2, 2007, Pages 108-120

  Möhlenkamp, Stefan ^a   Moebus, Susanne ^a   Schmermund, Axel ^b   Lehmann, Nils ^a   Hoffmann, Barbara ^a   Neumann, Till ^a   Stang, Andreas ^c   Dragano, Nico ^d   Kerkhoff, Gert ^e   Naber, Christoph ^a   Kälsch, Hagen ^a   Beck, Eva Maria ^a   Bröcker Preuss, Martina ^a   Kröger, Knut ^a   Budde, Thomas ^e   Siegrist, Johannes ^d   Mann, Klaus ^a   Jöckel, Karl Heinz ^a   Erbel, Raimund ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b CARDIOANGIOLOGISCHES CENTRUM BETHANIEN   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e ALFRIED KRUPP KRANKENHAUS   (Germany)

Author keywords

Atherosclerosis; Heinz Nixdorf Recall Study; Progression of CAC; Risk stratification

Indexed keywords

AORTA VALVE DISEASE; ARTERY CALCIFICATION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; GENETIC VARIABILITY; HEALTH STATUS; HEART FAILURE; HUMAN; INCIDENCE; METABOLIC SYNDROME X; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SOCIAL PSYCHOLOGY; AGED; CALCINOSIS; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; GERMANY; INFORMATION PROCESSING; MALE; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT;

AGED; CALCINOSIS; CORONARY ARTERIOSCLEROSIS; DATA COLLECTION; DISEASE PROGRESSION; FEMALE; GERMANY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 34248562422     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-007-2982-3     Document Type: Article

References (125)

1. Schmermund A, Möhlenkamp S, Stang A, et al., for the Heinz Nixdorf Recall Study Investigative Group. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf Recall study. Am Heart J 2002;144:212-8.
2. Shaw LJ, Ragii P, Schisterman E, et al. Prognostic value of cardiac risk factors and CAC screening for all-cause mortality. Radiology 2003;228:826-33.
3. Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 2003;107:2571-6.
4. Pletcher MJ, Tice JA, Pignone W, et al. Using the CAC Score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med 2004;164:1285-92.
5. Greenland P, LaBree L, Azen SP, et al. CAC Score combined with Framingham Score for risk prediction in asymptomatic individuals. JAMA 2004;291:210-5.
6. Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary disease risk factors, CRP, and atherosclerotic cardiovascular disease events. J Am Coll Cardiol 2005;46:158-65.
7. Vliegenthart R, Oudkerk M, Hofmann A, et al. Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation 2005;112:572-7.
8. LaMonte MJ, FitzGerald SJ, Church TS, et al. CAC Score and CHD events in a large cohort of asymptomatic men and women. Am J Epidemiol 2005;162:1-9.
9. Taylor AJ, Bindeman J, Feuerstein I, et al. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors. Mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J Am Coll Cardiol 2005;46:807-14.
10. Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of CAD by cardiac CT: a scientific statement from the AHA Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006;114;1761-91.
11. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on CAC scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain. A report of the ACC Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on EBCT). Developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. Circulation 2007;115:403-26.
12. Schmermund A, Möhlenkamp S, Mathes P, et al. Bedeutung der Koronarkalkbestimmung in der Primärprävention. Z Kardiol 2005;94:Suppl 3:III/79-87.
13. Naghavi M, Falk E, Hecht HS, et al. From vulnerable plaque to vulnerable patient - part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report. Am J Cardiol 2006;98:Suppl:2H-15H.
14. Leitlinien zur kardiovaskulären Prävention. Z Kardiol 2005;94:Suppl 3:III/1-115.
15. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
16. Grundy SM, Pasternack R, Greenland P, et al. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. Circulation 1999;100:1481-92.
17. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) study. Circulation 2002;105:310-5.
18. 4S Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
19. Sheperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart diseases with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
20. Greenland P, Abrams J, Aurigemma GP, et al. Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention. Noninvasive tests of atherosclerotic burden. Circulation 2000;101:e16-22.
21. Fuster V, Badimon JJ, Badimon L. Clinical-pathological correlations of coronary disease progression and regression. Circulation 1992;86:Suppl:III1-11.
22. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71:699-708.
23. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death. A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-75.
24. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001;103:934-40.
25. Erbel R, Siffert W, Möhlenkamp S, et al. Prävention der KHK durch Risikostratifizierung - eine neue Sichtweise mit Konsequenzen für die Gesundheitsfürsorge. Dtsch Med Wochenschr 2003;128:330-6.
26. Erbel R, Budde T, Kerkhoff G, et al. Understanding the pathophysiology of the arterial wall: which method should we choose? Electron-beam computed tomography. Eur Heart J 2002;4:F47-53.
27. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993;87:1067-75.
28. Schmermund A, Baumgart D, Möhlenkamp S, et al. Natural history and topographic pattern of progression of coronary calcification in symptomatic patients - an EBCT study. Arterioscler Thromb Vasc Biol 2001;21:421-6.
29. Birgelen C von, Hartmann M, Mintz GS, et al. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (> 12 months) follow-up intravascular ultrasound. Circulation 2003;108:2757-62.
30. Achenbach S, Daniel WG. Current role of cardiac computed tomography. Herz 2007;32:97-107.
31. Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol 2002;156:871-81.
32. Schmermund A, Möhlenkamp S, Behrenbein S, et al. Population-based assessment of subclinical coronary atherosclerosis using EBCT. Atherosclerosis 2006;185:177-82.
33. Raggi P, Cooil B, Shaw L, et al. Progression of coronary calcium on serial EBT scanning is greater in patients with future myocardial infarction. Am J Cardiol 2003;92:827-9.
34. Raggi P, Callister TQ, Shaw LJ. Progression of CAC and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol 2004;24:1272-7.
35. Shemesh J, Koren-Morag N, Apter S, et al. Accelerated progression of coronary calcification: four-year follow-up in patients with stable coronary artery disease. Radiology 2004;233:201-9.
36. Callister TQ, Raggi P, Cooil B, et al. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by EBCT. N Engl J Med 1998;339:1972-8.
37. Budoff MJ, Lane KL, Bakhsheshi H, et al. Rates of progression of coronary calcium by EBT. Am J Cardiol 2000;86:8-11.
38. Schmermund A. Progression of coronary calcium. Herz 2001;26:278-86.
39. Budoff MJ, Raggi P. Coronary artery disease progression assessed by EBCT. Am J Cardiol 2001;88:Suppl:46E-50E.
40. Hecht HS, Harman SM. Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary prevention as determined by electron beam tomography. Am J Cardiol 2003;91:42-5.
41. Hecht HS, Harman SM. Relation of aggressiveness of lipid-lowering treatment to changes in calcified plaque burden by EBT. Am J Cardiol 2003;92:334-6.
42. Budoff MJ, Yu D, Nasir K, et al. Diabetes and progression of coronary calcium under the influence of statin therapy. Am Heart J 2005;149:695-700.
43. Achenbach S, Ropers D, Pohle K, et al. Influence of lipid-lowering therapy on the progression of CAC: a prospective evaluation. Circulation 2002;106:1077-82.
44. Möhlenkamp S, Schmermund A, Budde T, et al. Aktuelle Studien zur Progression koronarer Kalzifikationen. MMW Fortschr Med 2007:im Druck.
45. Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E. J Am Coll Cardiol 2005;46:166-72.
46. Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women. Beyond endorsed lipid lowering with EBT scanning (BELLES). Circulation 2005;112:563-71.
47. Schmermund A, Achenbach S, Budde T, et al. Intensive dose atorvastatin therapy does not attenuate the progression of coronary calcification compared with standard dose atorvastatin therapy over twelve months: a multicenter, randomized, double-blind trial. Circulation 2006;113:427-37.
48. Houslay ES, Cowell SJ, Prescott RJ, et al., on behalf of the Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression (SALTIRE) Trial Investigators. Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart 2006;92:1207-12.
49. Snell-Bergeon JK, Hokanson JE, Jensen L, et al. Progression of CAC in type 1 diabetes: the importance of glycemic control. Diabetes Care 2003;26:2923-8.
50. Cassidy AE, Bielak LF, Zhou Y, et al. Progression of subclinical coronary atherosclerosis. Does obesity make a difference? Circulation 2005;111:1877-82.
51. Mehrotra R, Budoff MJ, Hokanson JE, et al. Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int 2005;68:1258-66.
52. Raggi P, Cooil B, Ratti C, et al. Progression of CAC and occurrence of myocardial infarction in patients with and without diabetes mellitus. Hypertension 2005;46:238-43.
53. Wong M, Edelstein J, Wollmann J, et al. Ultrasonic-pathological comparison of the human arterial wall: verification of IMT. Arterioscler Thromb 1993;13:482-6.
54. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk In Communities (ARIC) study. Am J Epidemiol 1997;146:483-94.
55. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk In Communities (ARIC) study. Am J Epidemiol 2000;151:478-87.
56. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study. N Engl J Med 1999;340:14-22.
57. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid artery IMT and risk of stroke and myocardial infarction: the Rotterdam study. Circulation 1997;96:1432-7.
58. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial IMT in predicting clinical coronary events. Ann Intern Med 1998;128:262-9.
59. Furberg CD, Adams HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-87.
60. Blankenhorn DH, Seltzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on carotid atherosclerosis: 2 and 4 year reduction of IMT measured by ultrasound. Circulation 1993;88:20-8.
61. Smilde TJ, Wissen SV, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP); a prospective, randomised double blind trial. Lancet 2001;357:577-81.
62. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid IMT. Circulation 2003;106:2055-60.
63. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7.
64. Hedblad B, Wikstrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid IMT: main results from the Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001;103:1721-6.
65. Wiklund O, Hulthe J, Wikstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3 year randomized trial. Stroke 2002;33:572-7.
66. Pitt B, Byington RP, Furberg CD, et al., for the PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000;102:1503-10.
67. Nathan DM, Lachin J, Cleary P, et al. Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid IMT in Type 1 diabetes mellitus. N Engl J Med 2003;348:2294-303.
68. Möhlenkamp S, Bauer M, Moebus S, et al. Koronarkalkquantifizierung und Intima-Media-Dickenmessung liefern unabhängige Information über die Ausprägung der subklinischen Arteriosklerose bei Männern - Ergebnisse aus der Heinz Nixdorf Recall Studie. Clin Res Cardiol 2006;95:Suppl 5:P1331 (http://ft2006.dgk.org/programm).
69. Sandholzer H, Hellenbrand W, Renteln-Kruse W, et al. STEP - europäische Leitlinie für das standardisierte evidenzbasierte präventive Assessment älterer Menschen in der medizinischen Primärversorgung. Dtsch Med Wochenschr 2004;129:Suppl 4:S183-226.
70. Kröger K, Stang A, Kondratieva J, et al. Prevalence of peripheral arterial disease - results of the Heinz Nixdorf Recall Study. Eur J Epidemiol 2006;21:279-85.
71. Ashley EA, Raxwal V, Froelicher V. The prevalence and prognostic significance of ECG abnormalities. Curr Probl Cardiol 2000;1:1-72.
72. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by ECG: prevalence, incidence and mortaility in the Framingham study. Ann Intern Med 1969;71:89-105.
73. De Bruyne MC, Hoes AW, Kors JA, et al. Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. Eur Heart J 1999;20:278-84.
74. De Bacquer D, De Backer G, Kornitzer M, et al. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease in men and women. Heart 1998;80:570-7.
75. Kors JA, de Bruyne MC, Hoes AW, et al. T axis as an indicator of risk of cardiac events in elderly people. Lancet 1998;352:601-5.
76. Robbins J, Nelson JC, Rautaharju PM, et al. Association between the length of the QT interval and mortality in the Cardiovascular Health Study. Am J Med 2003;115: 689-94.
77. Wood D, Durrington P, McInnes G, et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80:Suppl 2:S1-29.
78. JNC. The 7th report of the Joint National Committee (JNC) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
79. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10.
80. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report. Circulation 2002;106:3143-421.
81. Möhlenkamp S, Schmermund A, Lehmann N, et al. Subclinical coronary atherosclerosis and resting ECG-abnormalities in an unselected general population. Atherosclerosis 2007:in press.
82. The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habits, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. J Chronic Dis 1978;31:201-306.
83. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA Task Force on Practice Guidelines - 2002 guideline update for exercise testing: summary article. Circulation 2002;106:1883-92.
84. Fowler-Brown A, Pignone M, Pletcher M, et al. US Preventive Services Task Force. Exercise tolerance testing to screen for CHD: a systematic review for the technical support for the US Preventive Services Task Torce. Ann Intern Med 2004;140:W9-24.
85. Lauer M, Froelicher ES, Williams M, et al. Exercise testing in asymptomatic adults. A statement for professionals from the AA Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2005;112:771-6.
86. Kligfield P, Lauer MS. Exercise electrocardiogram testing - beyond the ST segment. Circulation 2006;114:2070-82.
87. Wei M, Kampert JB, Barlow CE, et al. Relationship between low cardiorespiratory fitness and mortality in normalweight, overweight, and obese men. JAMA 1999;282:1547-53.
88. Möhlenkamp S, Roggenbuck U, Schmermund A, et al., for the Heinz Nixdorf Recall Study Investigators. Heart rate recovery after bicycle stress testing is delayed in subjects with elevated coronary atherosclerotic plaque burden in the general population. Circulation 2004;110:Suppl:III-562.
89. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/AHA conference on scientific issues related to definition. Circulation 2004;109:433-8.
90. WHO. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: WHO, 1999 (http://whqlibdoc.who. int/hq/1999, page: WHO_NCD_NCS_99.2.pdf).
91. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005.
92. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
93. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304.
94. Moebus S, Hanisch JU, Neuhäuser M, et al. Assessing the prevalence of the metabolic syndrome according to NCEP ATP III in Germany: feasibility and quality aspects of a two step approach in 1550 randomly selected primary health care practices. GMS Ger Med Sci 2006;4:Doc07 (http://www.egms.de/en/gms/2006- 4/000036.shtml).
95. Möhlenkamp S, Schmermund A, Lehmann N, et al. Eine Prädisposition zum metabolischen Syndrom ist mit einer erhöhten entzündlichen koronaren Plaquelast bei Frauen mit niedrigem Framingham-Risiko assoziiert. Clin Res Cardiol 2006;95:Suppl 5:P1329 (http://ft2006.dgk.org/programm).
96. Michos ED, Nasir K, Braunstein JB, et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis 2006;184:201-6.
97. Rosvall M, Ostergren PO, Hedblad B, et al. Socioeconomic differences in the progression of carotid atherosclerosis in middle-aged men and women with subclinical atherosclerosis in Sweden. Soc Sci Med 2006;62:1785-98.
98. Dragano N, Verde PE, Moebus S, et al., on behalf of the Heinz Nixdorf Recall Study Group. Subclinical coronary atherosclerosis is more pronounced in men and women with lower socioeconomic status. Associations in a population based study. Eur J Cardiovasc Prev Rehabil 2007:in press.
99. Brook RD, Franklin B, Cascio W, et al. Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the AHA. Circulation 2004;109:2655-71.
100. Schulz H, Harder V, Ibald-Mulli A, et al. Cardiovascular effects of fine and ultrafine particles. J Aerosol Med 2005;18:1-22.
101. Suwa T, Hogg JC, Quinlan KB, et al. Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol 2002;39:935-42.
102. Sun Q, Wang A, Jin X, et al. Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. JAMA 2005;294:3003-10.
103. Hoffmann B, Moebus S, Stang A, et al. Residence close to high traffic and prevalence of coronary heart disease. Eur Heart J 2006;27:2696-702.
104. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for ACE is a potent risk factor for myocardial infarction. Nature 1992;359:641-4.
105. Naber CK, Frey UH, Oldenburg O, et al. Relevance of the NOS3 T-786C and G894T variants for cholinergic and adren ergic coronary vasomotor responses in man. Basic Res Cardiol 2005;100:453-60.
106. Naber CK, Baumgart D, Heusch G, et al. Role of the eNOS Glu298Asp variant on the GNB3 825T allele dependent determination of α-adrenergic coronary constriction. Pharmacogenetics 2003;13:279-84.
107. Naber CK, Husing J, Wolfhard U, et al. Interaction of the ACE D allele and the GNB3 825T allele in myocardial infarction. Hypertension 2000;36:986-9.
108. Chakravarti, A. Population genetics - making sense out of sequence. Nat Genet 1999;21:56-60.
109. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
110. Kragelund C, Gronning B, Kober L, et al. N-terminal pro B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75.
111. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-4.
112. Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of "degenerative" valvular aortic stenosis: histological and immunohistochemical studies. Circulation 1994;90:844-53.
113. Olsson M, Dalsgaard C, Haegerstrand A, et al. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1994;23:1162-70.
114. O'Brien KD, Reichenbach DD, Marcovina SM, et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of "degenerative" valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996;16:523-32.
115. Olsson M, Thyberg J, Nilsson J. Presence of oxidized LDL in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999;19:1218-22.
116. Palta S, Pai AM, Gill KS, et al. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000;101:2497-502.
117. Nassimiha D, Aronow WS, Ahn C, et al. Association of coronary risk factors with progression of valvular aortic stenosis in older persons. Am J Cardiol 2001;87:1313-4.
118. Pohle K, Mäffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001;104:1927-32.
119. Rajamannan, NM, Subramaniam M, Stock SR, et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005;91:806-10.
120. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611-7.
121. Cowell SJ, Newby DE, Prescott RJ, et al., for the Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97.
122. Agmon Y, Khandheria BK, Meissner I, et al. Is aortic dilatation an atherosclerosis-related process? Clinical, laboratory, and transesophageal echocardiographic correlates of thoracic aortic dimensions in the population with implications for thoracic aortic aneurysm formation. J Am Coll Cardiol 2003;42:1076-83.
123. Erbel R, Alfonso F, Boileau C, et al. Task Force on Aortic Dissection of the European Society of Cardiology. Diagnosis and management of aortic dissection. Eur Heart J 2001;22:1642-81.
124. Erbel R, Eggebrecht H. Aortic dimensions and the risk of dissection. Heart 2006;92:137-42.
125. Bild DE, Detrano R, Peterson D, et al. Differences in coronary calcification. The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2005;111:1313-20.